We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
Read MoreHide Full Article
AbbVie Inc. ((ABBV - Free Report) ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. Top-line results from the first of the two pivotal phase III studies on elagolix (ELARIS UF-I) revealed that at six month, elagolix, in combination with low-dose add-back hormone therapy, reduced heavy menstrual bleeding compared to placebo. 68.5% (p<0.001) of women with uterine fibroids achieved clinical response.
The study also met all ranked secondary endpoints at month six.
Hypoestrogenic effects, such as hot flush and reduction in bone mineral density, from elagolix treatment, were observed in the study. However, the overall safety profile for elagolix was consistent with what was observed in phase II studies in uterine fibroids. Data from the phase III study will support regulatory submissions for elagolix and will be presented at an upcoming medical conference.
Elagolix is under review in the United States for the management of endometriosis with associated pain.
So far this year, AbbVie’s shares price have returned 92.1%, comparing favorably with 11.1% gain recorded by the industry.
We note that there are many other companies that have pipeline candidates being evaluated for uterine fibroids. Bayer (BAYRY - Free Report) is evaluating vilaprisan in women suffering from uterine fibroids in a phase III ASTEROID study
Allergan’s pipeline candidate, ulipristal acetate’s is under regulatory review in the United States. The company expects the FDA to give its decision in the first half of 2018.
In a separate press release, AbbVie also announced that it has inked anexclusive strategic collaboration and option agreement with a clinical-stage gene therapy company, Voyager Therapeutics (VYGR - Free Report) , to develop and commercialize vectorized antibodies for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Per the deal, Voyager will receive an upfront cash payment of $69 million, as well as up to $155 million in potential preclinical and phase I option payments. Following the announcement of the deal, shares of Voyager rose almost 15%.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
AbbVie Inc. ((ABBV - Free Report) ) along with partner Neurocrine Biosciences, announced that the phase III study oftheir late stage candidateelagolix met its primary endpoint in women with uterine fibroids. Top-line results from the first of the two pivotal phase III studies on elagolix (ELARIS UF-I) revealed that at six month, elagolix, in combination with low-dose add-back hormone therapy, reduced heavy menstrual bleeding compared to placebo. 68.5% (p<0.001) of women with uterine fibroids achieved clinical response.
The study also met all ranked secondary endpoints at month six.
Hypoestrogenic effects, such as hot flush and reduction in bone mineral density, from elagolix treatment, were observed in the study. However, the overall safety profile for elagolix was consistent with what was observed in phase II studies in uterine fibroids. Data from the phase III study will support regulatory submissions for elagolix and will be presented at an upcoming medical conference.
Elagolix is under review in the United States for the management of endometriosis with associated pain.
So far this year, AbbVie’s shares price have returned 92.1%, comparing favorably with 11.1% gain recorded by the industry.
We note that there are many other companies that have pipeline candidates being evaluated for uterine fibroids. Bayer (BAYRY - Free Report) is evaluating vilaprisan in women suffering from uterine fibroids in a phase III ASTEROID study
Allergan’s pipeline candidate, ulipristal acetate’s is under regulatory review in the United States. The company expects the FDA to give its decision in the first half of 2018.
In a separate press release, AbbVie also announced that it has inked anexclusive strategic collaboration and option agreement with a clinical-stage gene therapy company, Voyager Therapeutics (VYGR - Free Report) , to develop and commercialize vectorized antibodies for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Per the deal, Voyager will receive an upfront cash payment of $69 million, as well as up to $155 million in potential preclinical and phase I option payments. Following the announcement of the deal, shares of Voyager rose almost 15%.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
Abbvie currently carries a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>